HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tomihisa Funyu Selected Research

poly-N-acetyllactosamine

6/2017A mechanism for evasion of CTL immunity by altered O-glycosylation of HLA class I.
2/2013Core2 O-glycan-expressing prostate cancer cells are resistant to NK cell immunity.
6/2012MUC1 carrying core 2 O-glycans functions as a molecular shield against NK cell attack, promoting bladder tumor metastasis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Tomihisa Funyu Research Topics

Disease

7Urinary Bladder Neoplasms (Bladder Cancer)
10/2017 - 01/2010
6Neoplasms (Cancer)
06/2017 - 06/2009
3Neoplasm Metastasis (Metastasis)
06/2017 - 06/2012
2Cardiovascular Diseases (Cardiovascular Disease)
04/2017 - 01/2017
2Renal Cell Carcinoma (Grawitz Tumor)
04/2017 - 02/2017
2Chronic Renal Insufficiency
02/2017 - 01/2012
1Hypertension (High Blood Pressure)
04/2017
1Urolithiasis
04/2017
1Hyperuricemia
01/2017
1Acidosis
10/2013
1Constipation
10/2013
1Prostatic Neoplasms (Prostate Cancer)
02/2013
1Chronic Kidney Failure (Chronic Renal Failure)
01/2013
1Peripheral Arterial Disease
01/2012
1Arteriovenous Fistula
01/2011
1Pathologic Constriction (Stenosis)
01/2011
1Carcinoma (Carcinomatosis)
06/2009
1Atherosclerosis
08/2008
1Pruritus (Itching)
08/2004

Drug/Important Bio-Agent (IBA)

3Polysaccharides (Glycans)IBA
06/2017 - 06/2012
3poly-N-acetyllactosamineIBA
06/2017 - 06/2012
2Galectin 3 (LGALS3)IBA
06/2017 - 06/2012
2CortactinIBA
06/2014 - 04/2014
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
02/2013 - 06/2012
2LigandsIBA
02/2013 - 06/2012
1Peptides (Polypeptides)IBA
06/2017
1HLA Antigens (Human Leukocyte Antigens)IBA
06/2017
1EnzymesIBA
06/2017
1Uric Acid (Urate)IBA
04/2017
1Hemoglobins (Hemoglobin)IBA
01/2017
1Actins (F Actin)IBA
04/2014
1Small Interfering RNA (siRNA)IBA
04/2014
1Matrix Metalloproteinases (MMPs)IBA
04/2014
1VimentinIBA
04/2014
1PlectinIBA
04/2014
1Sevelamer (RenaGel)FDA Link
10/2013
1bixalomerIBA
10/2013
1Glycoproteins (Glycoprotein)IBA
02/2013
1Granzymes (Granzyme)IBA
02/2013
1Complementary DNA (cDNA)IBA
01/2013
1Mucin-1 (CA 15-3 Antigen)IBA
06/2012
1AST 120IBA
01/2012
1Shape Memory AlloysIBA
01/2011
1nitinolIBA
01/2011
1Polyurethanes (Polyurethane)IBA
01/2011
1matrigelIBA
01/2010
1Eosine Yellowish-(YS) (Eosin)IBA
06/2009
1AdiponectinIBA
08/2008
1CalciumIBA
08/2004
1IonsIBA
08/2004

Therapy/Procedure

4Renal Dialysis (Hemodialysis)
10/2013 - 08/2008
2Nephrectomy
04/2017 - 02/2017
1Cystectomy
10/2017
1Renal Replacement Therapy (Therapies, Renal Replacement)
01/2013
1Salvage Therapy
01/2011
1Stents
01/2011
1Lasers (Laser)
01/2010